Scholarlink

Introduction <p>Postoperative atrial fibrillation (POAF) is a pathological condition observed commonly among patients who underwent cardiac surgeries. It has been associated with increased hospital stay length, healthcare costs, morbidity, and mortality. Recent studies have evaluated colchicine’s innate role as an anti-inflammatory in preventing POAF. This is due to its ability to reduce the remodeling of the atrial walls. In this review, we focus on the proposed mechanisms, efficacy, and future directions in preventing POAF with colchicine.</p> Methodology <p>This study incorporated six (6) randomized controlled trials and three (3) systematic reviews and meta-analyses of randomized controlled trials of varying sample sizes involving individuals with cardiovascular comorbidities such as diabetes, coronary artery disease, and hypertension after carefully searching the data available on colchicine’s efficacy in POAF.</p> Results <p>The reviewed randomized controlled trials found the following—three (3) studies found that colchicine significantly reduced POAF compared to placebo; two (2) studies found that colchicine reduced the occurrence of POAF, but the findings were not statistically significant; and one study found no change between the treatment group and placebo. Aside from reducing POAF incidence in patients treated with colchicine, it was observed in the studies that patients noted improved quality of life and reduced hospital stay. Additionally, patients reported adverse effects such as increased rates of infections and gastrointestinal side effects such as diarrhea. This review also conducted a comparative analysis of colchicine with conventional therapies such as beta-blockers and amiodarone, and it was noted that colchicine can serve as a supplementary option.</p> Conclusion <p>Large-scale studies with larger sample sizes and more extensive clinical trials must be conducted to prospectively scrutinize colchicine’s definite role in POAF and its application in a more diverse population of patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Role of Colchicine in the Prevention of Postoperative Atrial Fibrillation: Mechanisms, Efficacy, and Future Directions

  • 期刊论文

  • 发表日期：

    2026年1月3日

查看全文
  • Ikponmwosa Jude Ogieuhi,
  • Victor Oluwatomiwa Ajekiigbe,
  • Chidera Stanley Anthony,
  • Christopher Adegbesan Abiodun,
  • Kenneth Kolo-Manma,
  • Chukwuemeka Christian Aghasili,
  • Falayi Taiwo Ayokunle,
  • Joan Oluwadamilola Ajayi,
  • Olufemi Akinmeji,
  • Boluwaduro Abasiekem Adeyemi,
  • Esther Bajo Tetteh

摘要

Introduction

Postoperative atrial fibrillation (POAF) is a pathological condition observed commonly among patients who underwent cardiac surgeries. It has been associated with increased hospital stay length, healthcare costs, morbidity, and mortality. Recent studies have evaluated colchicine’s innate role as an anti-inflammatory in preventing POAF. This is due to its ability to reduce the remodeling of the atrial walls. In this review, we focus on the proposed mechanisms, efficacy, and future directions in preventing POAF with colchicine.

Methodology

This study incorporated six (6) randomized controlled trials and three (3) systematic reviews and meta-analyses of randomized controlled trials of varying sample sizes involving individuals with cardiovascular comorbidities such as diabetes, coronary artery disease, and hypertension after carefully searching the data available on colchicine’s efficacy in POAF.

Results

The reviewed randomized controlled trials found the following—three (3) studies found that colchicine significantly reduced POAF compared to placebo; two (2) studies found that colchicine reduced the occurrence of POAF, but the findings were not statistically significant; and one study found no change between the treatment group and placebo. Aside from reducing POAF incidence in patients treated with colchicine, it was observed in the studies that patients noted improved quality of life and reduced hospital stay. Additionally, patients reported adverse effects such as increased rates of infections and gastrointestinal side effects such as diarrhea. This review also conducted a comparative analysis of colchicine with conventional therapies such as beta-blockers and amiodarone, and it was noted that colchicine can serve as a supplementary option.

Conclusion

Large-scale studies with larger sample sizes and more extensive clinical trials must be conducted to prospectively scrutinize colchicine’s definite role in POAF and its application in a more diverse population of patients.